Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Ophthalmology

We are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting- edge research. Vision loss affects 253 million people worldwide, presenting a major global health problem and diseases of the retina are among the main causes of visual impairment globally.

We have the broadest late stage retina pipeline including treatments for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). Our robust early stage pipeline also includes gene therapies and treatments for geographic atrophy (GA).

Our experienced team of ophthalmologists, scientists and researchers are working to develop innovative solutions that have the potential to redefine standards of care for retinal diseases.

Partnering opportunities we are looking for:

  • Retinal diseases and long acting ocular drug delivery solutions
  • Glaucoma and dry eye disease

Example partnerships

Forsight Vision4 – Acquisition to acquire Port Delivery system for long-acting ocular delivery

Ionis – collarabotion to develop IONIS-FB-LRx targeting Factor B (FB) for a broad range of diseases including Geographic Atrophy (GA) and dry age-related macular degeneration (AMD)

4D Molecular Therapeutics – collaboration and license agreement to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need.

Your dedicated partnering leads in Ophthalmology


Tom Zioncheck, Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering


J.C. Lopez, Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering